EMD Serono and Pfizer To Promote NSCLC Therapy
Lung cancer News, News
Biopharmaceutical company EMD Serono has initiated co-promotion of XALKORI (crizotinib), an FDA-approved treatment for patients with non-small cell lung cancer (NSCLC), in collaboration with the company that produced the therapy, Pfizer. The ... Read more